Time filter

Source Type

Warsaw, Poland

Sliwczynski A.,Centrala NFZ | Tkacz A.,BioMedical IT Mikroprzedsiebiorstwo | Kowalski A.,Centrala NFZ | Wojcik-Klikiewicz B.,Centrala NFZ | And 6 more authors.
Nowotwory | Year: 2011

Results. According to the NFZ data, the average number of newly diagnosed cases of colorectal cancer was 16006 +/- 1721 for women and 17352 +/- 1335 for men in the years 2006-2009. The total number of treated patients was 39987 +/- 4110 for women and 43846 +/- 6421 for men. In each subsequent year, the number of treated patients increased by 1.300. A statistically significant difference was found in the standard distribution of the population size of age groups for men and women. This difference was not confirmed for non-standard distributions. The 70-74 age group constitutes the median for women, while for men, it is the 75-79 age group. According to the average standardized data of the NFZ, 67/100000 of new cases of cancer were registered for women and 75/100000 for men. Also, a statistically significant difference between the relative distributions of age groups was observed both according to KRN and NFZW for men and women in 2006 and only for women in 2007. The Kuyavian-Pomeranian, Masovian and Silesian Voivodeships stand out as having a relatively high potential for the treatment of colorectal cancer. Conclusions. The number newly diagnosed cases should be considered as slightly overestimated, while the KRN data seem to be understated. The growing trend in the number of treated patients is to be understood as an expression of increased availability of oncological treatment for patients. The observed larger size of the male population compared with women is reflected especially after the age of 70. and may be caused by civilisation factors. The comparison of NFZ data with the KRN data also makes it possible to put forward a hypothesis about the epidemiological nature of data collected by the NFZ, reflecting the actual tendencies of the disease incidence in the population. Source

Sliwczynski A.,Medical University of Lodz | Rzeznicki A.,Medical University of Lodz | Czeleko T.,Centrala NFZ | Seroczynski P.,Asseco Poland | And 4 more authors.
Nowotwory | Year: 2014

Introduction: Cancer related illnesses are a serious problem due to the always increasing number of such illnesses and the high cost of diagnosis and treatment. The increase in the ratio of elderly people together with the higher risk of exposure to harmful environmental factors and the development of diagnostic methods result in an increased number of diagnosed cancers. The aim of the work was to determine the population of the persons diagnosed with cancer in Poland, evaluate the tax payers' expenses connected with anti-cancer treatment and evaluate costs related to the introduction of the state-of-the-art treatment methods of the ill diagnosed with cancers. Material and methods: In order to carry out analyses of report information in the NHF data bases, an analytical module was created called the Illness Treatment Register (ITL). This enables downloading of information from the database and presenting it in real time. In the analysis, a method of evaluating the cost of introducing the innovation was assumed. Namely it was assumed that the cost of innovation is the value of funds expended by the public tax payers in a given year that remain, after extrapolation of therapy costs from the previous year per number of ill persons in a given year. The analysis did not consider the value of the infation index. The PESEL number was considered to be the unique identity number of the ill person. An excel calculation sheet was used in the data analysis which was carried out with the use of all items existing in the database, not diferentiating the degree of credibility of diagnosis confrmation. Results: The number of all the established persons diagnosed with cancer between the years 2002 and 2011 increased annually and reached over 1 million people in 2011 who were treated because of cancers. The average yearly dynamics of the patient numbers compare to the previous year, oscillated around +11%. Diagnosis that throughout the whole tested period exceeded 10% of the budget allocated for the oncological diagnoses, included breast cancer (C50) - 14.41% of the budget and exceeded the average annual cost for oncological diagnoses by nearly 1400%, and bronchi and lungs cancer (C34) - 10.5% of the budget and exceeded the average annual cost for oncological diagnoses by 1018%. Diagnosis with the highest annual average in the anaysed period were breast cancer (C50) - 566 944 649 PLN and bronchi and lungs cancer (C34) - 412 877 994 PLN. The above mentioned cancers were also the diagnoses of the highest number of health services between the years 2002 and 2011. Conclusions: The analyses showed that from over 100 groups of diagnosed cancers, there are around 35 that are relevant from the point of view of social epidemiology. This indicates that the National Cancer Prevention Programme should treat these illnesses with a high priority and it is for them that a detailed strategy of action ought to be worked out. There are about 20 groups of diagnoses where the calculated cost of innovation exceed 50 million PLN throughout the last three years: for cancers where new medicines were introduced. There is a great and sustaining hiatus in the analysed period (around 50%) between the reported diagnoses and the confrmed diagnoses for the ill persons that are treated. This requires more detailed analyses. Source

Tkacz A.,BioMedical IT | Sliwczynski A.,Centrala NFZ | Krajewski-Siuda K.,Wydzial Zdrowia Publicznego Slaski University Medyczny | Krajewski-Siuda K.,Jagiellonian University | Paszkiewicz J.,Centrala NFZ
Nowotwory | Year: 2010

Aim of the study. The aim of the paper is to evaluate the value of the data collected by the Polish National Health Fund (NFZ, Narodowy Fundusz Zdrowia) and analysing them in terms of number of patients in different age groups. The second aim is to estimate the changes in the availability of treatment in Poland in the years 2004-2009, depending on the area of residence or location of medical facility. Material and methods. The paper discusses the data submitted to the NFZ in the years 2004-2009, regarding oncology services with drug technology covered by public funds. These data include reports of over 169,000 treated women and over 150,000 treated men. The total cost of treatment in both groups was 1,554,737,791 PLN and 1,489,237,281 PLN, respectively. Results. The analysis of the obtained data revealed a significant increase in the number of treated patients in the following periods: 2004-2006 and 2007-2009. In the studied period, the increase in the cost of treatment significantly exceeded the tendency resulting from the increase in the number of treated patients. Furthermore, the analysis in respect to the number of beneficiaries, in particular age groups, revealed a significant increase in the number of women aged 30-100 and men aged 45-100 allocated to the chemotherapy group. Women aged 60-65 and men aged 70-75 were the most common beneficiaries of the system regarding chemotherapy. The territorial distribution of patients and the cost of treatments showed quite significant diversity in the respective voivodships. The phenomenon of intense patient migration from voivodships with worsening infrastructure, in terms of oncology treatment, to voivodships with better structural and personal potential, was also observed. Conclusions. The paper revealed that the data collected by the NFZ can be a valuable source of information on the number, age structure of population and the cost of hospital treatment of chemotherapy. Source

Dworski M.,Centrala NFZ | Sliwczynski A.,Centrala NFZ | Tkacz A.,BioMedical IT Mikroprzedsibiorstwo | Wojcik-Klikiewicz B.,Centrala NFZ | And 3 more authors.
Nowotwory | Year: 2011

Aim of the thesis. The aim of the paper is to estimate the number of patients with newly diagnosed lung cancer (according to the National Health Fund) in the years 2006-2009, to analyse time-related trends, and to compare the obtained results with the information stored at the National Cancer Registry (NCR). We also examined the relationship between the standardised number of new patients (according to the National Health Fund) and the sales volume of tobacco products (per capita). Materials and method. WE analysed data concerning malignant lung cancer (C33-C34) sent to the National Health Fund in the years 2004-2009 for all kinds of services. Results. The average number of new patients with diagnosed lung cancer (C33-C34), according to the data collected by the National Health Fund in the years 2006-2009 in Poland, was 11,196 for women and 23,629 for men. Hospital treatment accounted for approx. 70% of the cases - among these patients only 40% received chemotherapy. A comparison of the National Health Fund data with the data collected by the National Cancer Registry showed that, according to the National Health Fund, the number of new cases of malignant lung carcinoma is larger. A geographic analysis revealed that populations from Poland's northern provinces are at the greatest risk of developing this malignancy. An examination of the relationship between the standardised number of new cases of lung cancer, according to the National Health Fund data, and the average level of spending on tobacco products calculated per 1 person showed, that there exists a statistically significant correlation between these values - Pearson's correlation coefficient of 0.48 (p=6.47z.ast;10-05). Conclusions. With the growing number of patients undergoing treatment, the number of new patients remained at the same level in the years 2006-2009, which may indicate greater accessibility of oncologic treatment in this period. It was impossible to determine whether the lack of correspondence between the National Health Fund and the National Cancer Registry results from insufficient reporting to the NCR concerning services other than hospital treatment or whether it reflects greater reporting to the National Health Fund, which includes not only confirmed cases, but also medical activities undertaken to confirm lung cancer. The examination of dependence between the standardised number of new patients (according to the National Health Fund) and the sales volumes of tobacco products (per capita) confirmed the existence of a positive correlation between these variables. Source

Discover hidden collaborations